PatientID: NC4172-1997

Okitobba 06, 2023

## Color Code

HR: High-Level Resistance
LR: Low-Level Resistance
IR: Intermediate Resistance

S: Susceptible

DRUG.CLASS	DRUG	RESISTANCE.PROFILE	DRMS.above.20.percent.prevalence	
PI	ATV	HR		
	DRV	LR		
	FPV	HR	I84V;L90M;G73S	
	IDV	HR		
	LPV	IR		
	NFV	HR		
	SQV	HR		
	TPV	IR		
NRTI	ABC	HR		
	AZT	HR		
	D4T	$^{ m HR}$		
	DDI	$^{ m HR}$	M41L;D67N;M184I;L210W;T215Y;K219R	
	FTC	$^{ m HR}$		
	LMV	$^{ m HR}$		
	TDF	$^{ m HR}$		
NNRTI	DOR	${f S}$		
	EFV	$\mathbf{S}$		
	ETR	${f S}$		
	NVP	$\mathbf{S}$		
	RPV	${f S}$		

## Appendix

## Drug abbreviations in full

DRUG.CLASS	ABBREVIATION	DRUG.NAME
	ATV	Atazanavir
	DRV	Darunavir
	FPV	Fosamprenavir
PI	IDV	Indinavir
11	LPV	Lopinavir
	NFV	Nelfinavir
	SQV	Saquinavir
	TPV	Tipranavir
	ABC	Abacavir
	AZT	Azidothymidine
	DFT	Stavudine
NRTI	DDI	Didanosine
	FTC	Emtricitabine
	LMV	Lamivudine
	TDF	Tenofovir
	DOR	Doravirine
	EFV	Efavirenz
NNRTI	ETR	Etravirine
	NVP	Nevirapine
	RPV	Rilpivirine
	BIC	Bictegravir
	CAB	Cabotegravir
INSTI	DTG	Dolutegravir
	EVG	Elvitegravir
	RAL	Raltegravir

## Comments

DRUG.CLASS	COMMENTS
PI	G73S/T/C/A are common non-polymorphic accessory mutations selected primarily by most PIs. They are associated with minimally reduced susceptibility to each of the PIs.  I84V is a nonpolymorphic substrate-cleft mutation selected by each of the PIs. I84V reduces susceptibility to LPV, ATV, and DRV.  L90M is a non-polymorphic PI-selected mutation that reduces susceptibility to ATV and to a lesser extent LPV.
	D67N is a non-polymorphic TAM associated with low-level resistance to AZT.  K219E/Q/N/R are accessory TAMS that usually occur in combination with multiple other TAMs.  L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and intermediate resistance to ABC and TDF.
	M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication.

NRTI	M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC
	and TDF susceptibility.
	T215Y/F are TAMs that causes intermediate/high-level resistance to AZT and potentially
	low-level resistance to ABC and TDF.
NNRTI	
INSTI	